Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 17th 2020

We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)‘ (ABSTRACT NUMBER: 412) was presented at the Virtual 2020 ASH Congress, 2–10 December 2020.

Questions

  1. What are the major challenges and unmet needs when treating relapsed/refractory multiple myeloma? (0:08)
  2. What is the mode of action of daratumumab, and pomalidomide and dexamethasone, and what is the rationale behind the Apollo trial? (0:42)
  3. What were the aims and design of the Apollo trial? (3:00)
  4. What were the major safety and efficacy findings presented at this year’s ASH congress? (4:20)
  5. What will be the next steps in the clinical development of daratumumab, and how may it fit into treatment strategies? (6:08)

Speaker Disclosures: Meletios-Athanasios Dimopoulos discloses honoraria from participation in advisory boards from Amgen, Takeda, Beigene, Janssen and BMS.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup